Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.
Related news for (PCVX)
- Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
- Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
- Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
- Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants